This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Breast Cancer
  • /
  • Phase III, Randomized, Double-Blind Study Comparin...
Journal

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early

Read time: 1 mins
Published:26th Jan 2018
Author: Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH et al.
Availability: Pay for access, or by subscription
Ref.:J Clin Oncol. 2018:JCO2017740126.
DOI:10.1200/JCO.2017.74.0126
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest